Literature DB >> 2770436

Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study.

Y F Liaw1, D Y Lin, T J Chen, C M Chu.   

Abstract

To examine the early stage of the natural course of liver cirrhosis, a prospective follow-up study was conducted in a series of 76 patients with recent development of cirrhosis during the course of chronic type B hepatitis. During a mean follow-up period of 34.4 months, 45 episodes of acute exacerbation were recorded; the majority of the episodes occurred within 2 years after entry. The calculated annual incidence of acute exacerbation was significantly higher in patients seropositive for hepatitis B e antigen (HBeAg) and/or hepatitis B virus (HBV)-DNA (25.9%) than in those without these markers (11.9%). Three-fourths of the acute exacerbations were attributable to the reactivation of HBV. Spontaneous HBeAg seroconversion to anti-HBe also occurred in the early phase, but less than 30% of the events were preceded by acute exacerbation. Late hepatitis B surface antigen clearance occurred in two patients. Hepatic decompensation, esophageal variceal bleeding and hepatocellular carcinoma developed relatively late in the course of the disease with a calculated annual incidence of 2.3%, 2.3% and 2.8%, respectively. Seven patients (9.2%) died of hepatic failure or variceal bleeding, usually more than 3 years after entry. The estimated 5-year survival rate was 80%. The results suggest that the natural events of chronic HBV infection, including exacerbation, seroconversion and its sequelae could occur after the development of cirrhosis. In addition, these events might be responsible for the clinicopathological changes and the outcomes of these cirrhotic patients.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2770436     DOI: 10.1111/j.1600-0676.1989.tb00405.x

Source DB:  PubMed          Journal:  Liver        ISSN: 0106-9543


  27 in total

1.  Relative predictive factors for hepatocellular carcinoma after HBeAg seroconversion in HBV infection.

Authors:  Kazumoto Murata; Kazushi Sugimoto; Katsuya Shiraki; Takeshi Nakano
Journal:  World J Gastroenterol       Date:  2005-11-21       Impact factor: 5.742

2.  Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study.

Authors:  Yi-Cheng Chen; Chia-Ming Chu; Chau-Ting Yeh; Yun-Fan Liaw
Journal:  Hepatol Int       Date:  2007-03       Impact factor: 6.047

3.  Chronic hepatitis B viral infection independently predicts renal outcome in type 2 diabetic patients.

Authors:  A Y S Cheng; A P S Kong; V W S Wong; W Y So; H L Y Chan; C S Ho; C W K Lam; J S Tam; C C Chow; C S Cockram; J C N Chan; P C Y Tong
Journal:  Diabetologia       Date:  2006-05-31       Impact factor: 10.122

4.  Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: a systematic review and pooled meta-analyses.

Authors:  Kali Zhou; Caitlin Contag; Evans Whitaker; Norah Terrault
Journal:  Lancet Gastroenterol Hepatol       Date:  2019-01-22

5.  Inferior Outcomes Associated with the Coexistence of Hepatocellular Carcinoma Recurrence and Hepatic Virus Reinfection After Living Donor Liver Transplantation.

Authors:  Kun-Ming Chan; Tsung-Han Wu; Chih-Hsien Cheng; Chen-Fang Lee; Ting-Jung Wu; Hong-Shiue Chou; Wei-Chen Lee
Journal:  J Gastrointest Surg       Date:  2019-02-04       Impact factor: 3.452

Review 6.  Natural course, therapeutic options and economic evaluation of therapies for chronic hepatitis B.

Authors:  Steven-Huy B Han
Journal:  Drugs       Date:  2006       Impact factor: 9.546

7.  Cost-effectiveness analysis of population-based screening of hepatocellular carcinoma: Comparing ultrasonography with two-stage screening.

Authors:  Ming-Jeng Kuo; Hsiu-Hsi Chen; Chi-Ling Chen; Jean Ching-Yuan Fann; Sam Li-Sheng Chen; Sherry Yueh-Hsia Chiu; Yu-Min Lin; Chao-Sheng Liao; Hung-Chuen Chang; Yueh-Shih Lin; Amy Ming-Fang Yen
Journal:  World J Gastroenterol       Date:  2016-03-28       Impact factor: 5.742

Review 8.  A rationalized approach to the treatment of patients infected with hepatitis B.

Authors:  Natravis R Cox; Keyur Patel; Hans L Tillmann
Journal:  Mol Diagn Ther       Date:  2014-04       Impact factor: 4.074

9.  Clinical experience of hepatic hemangioma undergoing hepatic resection.

Authors:  Hsiu-Pei Tsai; Long-Bin Jeng; Wei-Chen Lee; Miin-Fu Chen
Journal:  Dig Dis Sci       Date:  2003-05       Impact factor: 3.199

10.  Expression of ezrin is associated with invasion and dedifferentiation of hepatitis B related hepatocellular carcinoma.

Authors:  Chun-Nan Yeh; See-Tong Pang; Tsung-Wen Chen; Ren-Ching Wu; Wen-Hui Weng; Miin-Fu Chen
Journal:  BMC Cancer       Date:  2009-07-15       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.